Global private equity and venture capital news and research

Posts Tagged ‘SR One’

23 December 2015

Altitude Life Science leads $40m Series B round in eFFECTOR Therapeutics

bacteria-811861_1920 Venture capital investor Altitude Life Science Ventures has led a $40m financing round for San Diego-based biopharmaceutical company eFFECTOR Therapeutics.

29 April 2015

GSK’s SR One among investors in CRISPR Therapeutics’ $89m fundraise

microscope7_sq SR One, the independent corporate venture capital arm of GlaxoSmithKline, was one of the lead investors in two rounds of financing totaling $89m for gene-editing biopharmaceutical company CRISPR Therapeutics.

1 April 2015

BDC Venture, SR One lead $21m Series D for Canadian biotech company

download (3) GlaxoSmithKline's venture capital arm SR One and BDC Venture Capital have co-led a $21m funding round for acute kidney injury specialist Thrasos Therapeutics.

14 October 2014

Bicycle Therapeutics VC backers return for £20m financing round

Bicycle Therapeutics A string of venture capital firms have renewed their commitment to UK-based biotech business Bicycle Therapeutics through a £20m financing round.

2 October 2014

Venture capital-backed Alios BioPharma sold to Johnson & Johnson for $1.75bn

sale-1306463-m Clinical stage biopharmaceutical company Alios BioPharma has been bought by multinational healthcare business Johnson & Johnson for around $1.75bn in cash.

24 July 2014

Flesh-eating bacteria specialist picks up $23m Series E led by SR One

pills-1111307-m SR One has led a $23m financing round for Atox Bio, which develops therapeutics for severe infections.

19 June 2014

Polaris backs biopharmaceutical startup Navitor’s $23.5m Series A

navitor Biopharmaceutical company Navitor Pharmaceuticals has raised a $23.5m Series A round from venture capital backer.

9 April 2014

Mystery investor joins venture backers in $41m Alios BioPharma Series B

virus2_sq A string of venture capital firms have renewed their backing of biotech business Alios BioPharma to help it develop treatments for respiratory viral diseases.

18 November 2013

Imperial Innovations heads up £20m investment in biotech developer Mission Therapeutics

UK technology commercialisation and investment firm Imperial Innovations has committed £4.5m of a £20m funding round for biotechnology company Mission Therapeutics alongside corporate venture investor Pfizer Venture Investments and existing investors Sofinnova Partners, SR One and Roche Venture Fund.

1 August 2013

RA Capital backs mammoth $60m Series C round for RNA Interference

RA Capital has helped emerging pharmaceutical company RNA Interference close an enormous $60m Series C financing round.

Page 1 of 212

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016